An emerging bacterium, chryseobacterium indologenes a case report and literature review

Abstract

Aerobic, Gram-negative, non-fermenting Chrysobacter endologins are bacilli that are inherently multidrug resistant. Among the infections that have been reported include keratitis, polymyositis, meningitis, pneumonia, and bacteremia in immobilized devices. We describe a rare instance of C. indolognes infection that resulted in bacteremia in a patient receiving intensive care and offer an analysis of cases that are comparable. This report emphasizes the importance of individualized treatment and promotes awareness about this organism as one of many emerging pathogens in immunocompromised adults who are often ICU residents. The most effective agents reported against C. indologes are the quinolones (gatifloxacin and levofloxacin) and trimethoprim-sulfamethoxazole (more than 95% sensitivity). Ciprofloxacin, cefepime, ceftazidime, piperacillin, and rifampin showed significant sensitivity. C. indologenes was obtained from blood cultures. Based on sensitivity, a successful response was observed with piperacillin/tazobactam. Guidelines for this pathogen's management should be taken into consideration given the rise in cases that have been documented in the literature. Levofloxacin, Ciprofloxacin, Piperacillin/Tazobactam, Trimethoprim/Sulfamethoxazole, Piperacillin/Tazobactam, and Rifampin were other effective antimicrobials against C. indologenes.